Optimi Health Stock Rises on Ibogaine Supply and Drug Development

By EC Assets · Published 8 June 2026

Optimi Health's stock rose following an ibogaine supply deal. The company has also started development of a finished drug product. This includes creating 50mg and 100mg ibogaine capsules at Optimi’s GMP site this summer. The development supports research efforts. A recent US executive order specifically named ibogaine compounds among those targeted for research. Health officials have identified ibogaine, a potent psychedelic, as a candidate for treating addiction. Ibogaine is also associated with cardiac risks. Medical research into ibogaine is in an early phase. The administration aims to determine its efficacy. One individual reported 20 days without cravings or withdrawal symptoms after ibogaine treatment for alcohol addiction. Researchers are currently exploring ibogaine. The plant-based compound is also being studied for its potential to reduce PTSD, depression, and anxiety in veterans with brain injuries and other health disorders. Long-term supply agreements can affect a company's long-term earnings potential. This article is intended for informational purposes only. It does not constitute investment advice.